CH:NOVN Stock Latest News

Novartis to build radioligand therapy site in Denton, Texas

CRM

PremiumThe Fly

6h ago

Novartis to present five abstracts on Rhapsido at AAAI meeting

PremiumThe Fly

2d ago

FDA to begin requiring on clinical trial

PremiumThe Fly

7d ago

FDA to begin requiring one clinical trial in drug approvals

BMY

PremiumThe Fly

7d ago

BMY

PremiumThe FlyNovartis announces Phase III RemIND trial met primary endpoint

7d ago

Novartis price target raised to $180 from $160 at TD Cowen

The Fly

Novartis price target raised to $180 from $160 at TD Cowen

8d ago

Novartis: Vanrafia’s Mixed Phase III Data and Modest EPS Growth Support Balanced Risk‑Reward and Hold Rating

Ratings

Novartis: Vanrafia’s Mixed Phase III Data and Modest EPS Growth Support Balanced Risk‑Reward and Hold Rating

9d ago

Novartis Vanrafia Phase III data supports slowing of kidney function decline

PremiumThe Fly

12d ago

Novartis price target raised to CHF 135 from CHF 125 at JPMorgan

PremiumThe Fly

13d ago

Novartis price target raised to EUR 135 from EUR 125 at Deutsche Bank

PremiumThe Fly

13d ago

Sustained Growth Beyond Patent Cliffs: Confidence in Novartis’ Pipeline-Driven Upside to 2030

PremiumRatings

14d ago

PremiumThe FlyNovartis’ treatment of progressive supranuclear palsy granted orphan designation

15d ago

Novartis downgraded to Hold from Buy at DZ Bank

The Fly

Novartis downgraded to Hold from Buy at DZ Bank

15d ago

Novartis breaks ground on biomedical research center in San Diego

The Fly

Novartis breaks ground on biomedical research center in San Diego

19d ago

Trump Trade: Argentina says U.S. to cut hundreds of tariffs

PremiumThe Fly

19d ago

Novartis price target lowered to CHF 132 from CHF 133 at Citi

PremiumThe Fly

20d ago

TrumpRx website using technology from GoodRx, STAT says

PremiumThe Fly

20d ago

Novartis: Resilient Core Performance and Medium-Term Pipeline Catalysts Support Buy Rating Despite Near-Term Guidance Softness

BMY

PremiumRatings

21d ago

Buy Rating on Novartis: Near-Term Guidance Headwinds Outweighed by Resilient Fundamentals, Advancing Pipeline, and Supportive Valuation

PremiumRatingsBuy Rating on Novartis: Near-Term Guidance Headwinds Outweighed by Resilient Fundamentals, Advancing Pipeline, and Supportive Valuation

21d ago

Novartis: Resilient Core Earnings, Conservative Guidance and Robust Pipeline Support Buy Rating and EPS Upside to 2030

Ratings

Novartis: Resilient Core Earnings, Conservative Guidance and Robust Pipeline Support Buy Rating and EPS Upside to 2030

21d ago

Novartis reports Q4 core EPS $2.03 vs. $1.98 last year

The Fly

Novartis reports Q4 core EPS $2.03 vs. $1.98 last year

21d ago